Header Logo

Connection

VIJAY NAMBI to Cholesterol, LDL

Back to Details
This is a "connection" page, showing publications VIJAY NAMBI has written about Cholesterol, LDL.
VIJAY NAMBI
Connection Strength
2.655
Cholesterol, LDL
  1. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
    View in: PubMed
    Score: 0.529
  2. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations. Curr Atheroscler Rep. 2015 Jan; 17(1):467.
    View in: PubMed
    Score: 0.337
  3. Persistent gaps in management and risk factor control among patients with atherosclerotic cardiovascular disease: All of us research program. Atherosclerosis. 2026 Jul; 418:120794.
    View in: PubMed
    Score: 0.186
  4. LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon. J Am Coll Cardiol. 2024 02 13; 83(6):665-668.
    View in: PubMed
    Score: 0.158
  5. Low-density lipoprotein cholesterol goals in the secondary prevention of cardiovascular diseases in the Indian population-Is 30 the new 70? J Clin Lipidol. 2020 Mar - Apr; 14(2):173-175.
    View in: PubMed
    Score: 0.120
  6. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.119
  7. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.114
  8. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.111
  9. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
    View in: PubMed
    Score: 0.107
  10. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. J Clin Lipidol. 2018 Sep - Oct; 12(5):1141-1145.
    View in: PubMed
    Score: 0.107
  11. Advances in the management of dyslipidemia. Curr Opin Cardiol. 2017 Jul; 32(4):348-355.
    View in: PubMed
    Score: 0.100
  12. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014 Dec; 2(6):600-7.
    View in: PubMed
    Score: 0.083
  13. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.067
  14. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
    View in: PubMed
    Score: 0.059
  15. Lipid management: considerations in acute coronary syndrome. Curr Cardiol Rep. 2008 Jul; 10(4):334-41.
    View in: PubMed
    Score: 0.054
  16. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006 Aug 21; 98(4A):34i-38i.
    View in: PubMed
    Score: 0.046
  17. The impact of genetic testing on physician practice in specialized cardiovascular clinics. J Clin Lipidol. 2026 03; 20(3):677-681.
    View in: PubMed
    Score: 0.045
  18. Treatment of severe hyperlipidemia and associated cardiovascular outcomes: Data from a large healthcare system. J Clin Lipidol. 2025 Sep-Oct; 19(5):1256-1263.
    View in: PubMed
    Score: 0.043
  19. Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2025 May; 25(3):293-306.
    View in: PubMed
    Score: 0.042
  20. ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Curr Atheroscler Rep. 2004 Sep; 6(5):353-8.
    View in: PubMed
    Score: 0.041
  21. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002 Dec 01; 113(8):625-9.
    View in: PubMed
    Score: 0.036
  22. Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
    View in: PubMed
    Score: 0.035
  23. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Curr Probl Cardiol. 2022 Jul; 47(7):101043.
    View in: PubMed
    Score: 0.034
  24. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.034
  25. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.017
  26. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011 Dec; 219(2):596-602.
    View in: PubMed
    Score: 0.017
  27. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009 Jun; 2(3):279-85.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.